drugset / Trial / NCT02651714

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

NCT02651714

Phase 2 Completed 168 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.

Timeline

Start
2016-01-19
Primary completion
2017-08-04
Completion
2017-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule Oral

Indications